With FDA rejection, Amag loses out on broader use of anemia drug Feraheme

The FDA dashed Amag Pharmaceuticals' hopes for its anemia drug Feraheme. The agency rejected Amag's application for broader use of the treatment for iron deficiency, citing a lack of evidence of its safety. The drug is approved to treat anemia in patients with chronic kidney disease, but Amag wanted to market it to a much broader group of anemia patients. Release | Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.